Insulin Lispro
- Generic Name
- Insulin Lispro
- Brand Names
- Admelog, Humalog, Humalog Mix, Humalog kwikpen, Liprolog, Lyumjev, Insulin lispro Sanofi, Lyumjev (previously Liumjev)
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 133107-64-9
- Unique Ingredient Identifier
- GFX7QIS1II
- Background
Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is release...
- Indication
本品尤其适用于下列情况：
1.经常发生低血糖的1型糖尿病者，使用本品可减少低血糖的发生率；
2.生活不规律，外出活动较多的用胰岛素治疗的糖尿病患者，本品快速、短效的特点有助于及时调整胰岛素的用量。
- Associated Conditions
- Diabetes Mellitus, Diabetic Ketoacidosis, Gestational Diabetes Mellitus (GDM)
- Associated Therapies
- -
Comparison of Glycaemic Fluctuation and Oxidative Stress Between Two Short-term Therapies for Type 2 Diabetes
- First Posted Date
- 2015-08-18
- Last Posted Date
- 2015-08-20
- Target Recruit Count
- 70
- Registration Number
- NCT02526810
- Locations
- 🇨🇳
Endocrinology department of the Third Affiliated Hospital of Sun Yet-san University, Guangzhou City, Guangdong, China
Single Dose Clamp Study to Evaluate Concentration-time Profile and Metabolic Activity of 3 Dose Levels of Afrezza and 3 Dose Levels of Insulin Lispro in Patients With Type 1 Diabetes Mellitus
- First Posted Date
- 2015-06-12
- Last Posted Date
- 2017-04-13
- Lead Sponsor
- Mannkind Corporation
- Target Recruit Count
- 30
- Registration Number
- NCT02470637
- Locations
- 🇩🇪
Investigational Site Number 276001, Neuss, Germany
Normal Versus Dual Wave Insulin Bolus for High-protein Food
- Conditions
- Interventions
- First Posted Date
- 2014-10-28
- Last Posted Date
- 2018-01-31
- Lead Sponsor
- Medical University of Warsaw
- Target Recruit Count
- 70
- Registration Number
- NCT02276859
- Locations
- 🇵🇱
Department of Pediatrics, Medical University of Warsaw, Poland, Warsaw, Poland
A Study to Compare Pharmacokinetics and Pharmacodynamics of SAR342434 to Insulin Lispro in Subjects With Type 1 Diabetes
- First Posted Date
- 2014-10-23
- Last Posted Date
- 2014-10-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 30
- Registration Number
- NCT02273258
- Locations
- 🇩🇪
Sanofi Administrative Office, Frankfurt, Germany
A Trial to Compare the PK and PD of Insulin Lispro Administered Into Different Tissues in Subjects With Diabetes Mellitus Type 1
- First Posted Date
- 2014-08-20
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Profil Institut für Stoffwechselforschung GmbH
- Target Recruit Count
- 18
- Registration Number
- NCT02221323
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, NRW, Germany
A Study To Compare the Effects of Insulin Peglispro and Glargine on Insulin Sensitivity and Meal Time Insulin Requirements in Type 2 Diabetics
- Conditions
- Interventions
- First Posted Date
- 2014-07-22
- Last Posted Date
- 2018-11-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 24
- Registration Number
- NCT02197520
- Locations
- 🇺🇸
Profil Institute for Clinical Research Inc, Chula Vista, California, United States
A Study to Compare and Measure the Effects of Insulin Peglispro (LY2605541) and Glargine on Meal Time Insulin Requirements
- Conditions
- Interventions
- First Posted Date
- 2014-06-02
- Last Posted Date
- 2019-03-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 28
- Registration Number
- NCT02152384
- Locations
- 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Neuss, Germany
A Study of LY2605541 and Insulin Lispro Mixture in Healthy Participants
- First Posted Date
- 2013-06-06
- Last Posted Date
- 2014-10-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 40
- Registration Number
- NCT01871493
- Locations
- 🇸🇬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Singapore, Singapore
CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)
- First Posted Date
- 2013-05-08
- Last Posted Date
- 2018-11-07
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 456
- Registration Number
- NCT01848990
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, call (858) 794-8889 8 AM to 5 PM Mon-Fri Pacific Standard Time, Madison, Wisconsin, United States
Pharmacokinetic and Injection Site Toleration of BIOD-238 and BIOD-250 Compared to Humalog® in Subjects With Type 1 Diabetes
- First Posted Date
- 2013-03-15
- Last Posted Date
- 2013-03-15
- Lead Sponsor
- Biodel
- Target Recruit Count
- 12
- Registration Number
- NCT01811849
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.